Sarepta Therapeutics’ (SRPT) “Sell” Rating Reaffirmed at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reiterated by HC Wainwright in a research report issued to clients and investors on Monday, August 25th,Benzinga reports.

Several other brokerages have also commented on SRPT. Sanford C. Bernstein initiated coverage on Sarepta Therapeutics in a research report on Tuesday, July 29th. They set a “market perform” rating and a $13.00 price objective on the stock. Piper Sandler boosted their price target on shares of Sarepta Therapeutics to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 29th. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $30.00 to $37.00 in a research note on Tuesday, July 29th. Robert W. Baird boosted their target price on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada decreased their price target on Sarepta Therapeutics from $25.00 to $23.00 and set a “sector perform” rating on the stock in a research note on Thursday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $43.50.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT traded down $0.14 during trading on Monday, reaching $18.20. 22,526,492 shares of the stock traded hands, compared to its average volume of 10,716,794. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $140.10. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The company has a 50-day moving average of $17.72 and a 200-day moving average of $46.58. The stock has a market capitalization of $1.78 billion, a P/E ratio of -20.92 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business’s revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.07 EPS. Analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after purchasing an additional 105 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sarepta Therapeutics by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after acquiring an additional 218 shares during the period. UMB Bank n.a. grew its holdings in shares of Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 276 shares during the period. State of Alaska Department of Revenue grew its holdings in shares of Sarepta Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company’s stock worth $713,000 after acquiring an additional 285 shares during the period. Finally, State of Michigan Retirement System grew its holdings in Sarepta Therapeutics by 1.3% during the first quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock valued at $1,461,000 after purchasing an additional 300 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.